Matthew Virag


Matthew Virag


Boston | One International Place, 40th Floor, 100 Oliver Street, Boston, MA, United States of America 02110-2605
+1 617 728 7112 | +1 617 426 6567


Matthew S. Virag focuses his practice on corporate and securities matters, including capital markets transactions, mergers and acquisitions, venture capital financing and general corporate governance. He advises a wide range of public and private companies, including life sciences clients, business development companies, private equity funds and operating companies, on both regulatory and transactional matters. 

In addition, Mr. Virag counsels public companies on compliance with SEC-reporting obligations under the Securities Exchange Act of 1934 and other securities laws, including annual, quarterly, and current reporting and proxy disclosure and related shareholder communications. He has also guided clients though hostile tender offers and proxy fights. 

  • Bicycle Therapeutics Limited, a UK biotechnology company, in the negotiation of a collaboration agreement with Bioverativ Inc. to discover, develop and commercialize innovative therapies for hemophilia and sickle cell disease in a deal worth $424.2 million plus royalties.
  • Business Development Corporation of America, a non-traded business development company, in its issuance of $150 million of senior unsecured notes, which was followed by an offering of $60 million of additional senior unsecured notes.
  • Differential Brands Group Inc., a NASDAQ-listed corporation now known as Centric Brands Inc., in its purchase of the majority of the North American wholesale, retail and e-commerce operations of Global Brands Group Holding Limited, a Hong-Kong listed branded apparel, footwear and fashion accessories company, for a purchase price of $1.38 billion.
  • GIC in its acquisition of a substantial equity stake (along with Silver Lake) in, a provider of online family history data and personal DNA testing.
  • Griffon Corporation in the acquisition of ClosetMaid Corporation, a market leader of home storage and organization products, from Emerson Electric Co. 
  • Griffon Corporation and its affiliates in connection with the acquisition of CornellCookson, a leading U.S. manufacturer and marketer of rolling steel door and grille products designed for commercial, industrial, institutional, and retail use.
  • Janssen Pharmaceuticals, Inc., a subsidiary of Johnson & Johnson, in a divestiture of rights and assets with respect to a respiratory diagnostic assay panel to Biocartis NV, a Belgian company.
  • Keefe, Bruyette & Woods, a subsidiary of Stifel Financial Corp, as lead underwriter and joint book-running manager, in respect of the issuance of $34.5 million in senior unsecured notes by CM Finance Inc, a BDC listed on the NASDAQ Global Select Market.
  • Monster Worldwide Inc., a publicly traded global online employment solution company, in its US$429 million sale to an affiliate of Randstad Holding nv.
  • Public Pension Capital (PPC) in connection with its acquisition of Viteos Fund Services, a leading provider of middle- and back-office technology and services for the investment management industry.
  • Remedy Pharmaceuticals, Inc., a privately-held, clinical stage pharmaceutical company, in a sale of substantially all of its assets to a wholly-owned subsidiary of Biogen Inc., in a deal worth $120 plus development and sales milestone payments and royalties. 
  • Steadview Capital Management in its minority equity investment in Dream11, Inc., the owner of a fantasy sports website. 
  • Northwestern University, B.A., 2007
  • Emory University School of Law, J.D., 2012, with Honors, Order of the Coif, Articles Editor of the Emory Law Journal
  • New York
  • Massachusetts